Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Fachpsychotherapie Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Annals of Hematology
Erschienen in:

10.05.2022 | Original Article

Mapping incidence and mortality of leukemia and its subtypes in 21 world regions in last three decades and projections to 2030

verfasst von: Rajesh Sharma, Chinmay Jani

Erschienen in: Annals of Hematology | Ausgabe 7/2022

Einloggen, um Zugang zu erhalten

Abstract

This study examines the burden of leukemia and its subtypes at the global, regional, and national levels in 21 world regions and 204 countries in the last three decades. The estimates of incidence, deaths, and age-standardized rates of leukemia for 21 regions and 204 countries for 1990–2019 were extracted from the Global Burden of Disease 2019 study. Average annual percentage change in 1990–2019 for 21 regions was utilized for projecting leukemia burden in 2030. Globally, there were 643,579 [586,980–699,729] incident cases and 334,592 [306,818–360,214] deaths in 2019 due to leukemia, up from 474,924 [388,559–560,550] cases and 263,263 [233,664–298,696] deaths in 1990. Between 1990 and 2019, the age-standardized incidence rate (ASIR) decreased from 9.6 [8.1–11.0] in 1990 to 8.2 [7.5–8.9] per 100,000 person-years in 2019, and the age-standardized mortality rate (ASMR) decreased from 5.8/100,000 [5.2–6.4] in 1990 to 4.3/100,000 [3.9–4.6] in 2019. Between 1990 and 2019, the ASIR decreased in majority of regions except Western Europe and high-income Asia Pacific, whereas the ASMR decreased in all 21 regions. In 2019, country-wise, the ASIR varied from 3.0/100,000 [2.3–3.7] in Palau to 35.1/100,000 [26.4–47.2] in San Marino and the ASMR spanned from 2.3/100,000 [1.7–2.8] in San Marino to 15.8/100,000 [12.0–20.4] in Syria. As per our projections, globally, there will be 720,168 incident cases and 367,804 deaths due to leukemia in 2030. Substantial improvements have been witnessed in leukemia mortality rates in all regions, especially high-income regions and countries. Health care policies focusing on diagnostic improvements, cancer registration, and newer therapeutics at reduced cost or with insurance coverage are needed in low and middle-income countries.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Ou Z, Yu D, Liang Y et al (2020) Analysis of the Global Burden of Disease study highlights the trends in death and disability-adjusted life years of leukemia from 1990 to 2017. Cancer Commun 40(11):598–610CrossRef
2.
Gupta S, Antillon FA, Bonilla M et al (2011) Treatment-related mortality in children with acute lymphoblastic leukemia in Central America. Cancer 117(20):4788–4795PubMedCrossRef
3.
Umeh CA, Garcia-Gonzalez P, Tremblay D, Laing R (2020) The survival of patients enrolled in a global direct-to-patient cancer medicine donation program: The Glivec International Patient Assistance Program (GIPAP). EClinicalMedicine 19:100257PubMedPubMedCentralCrossRef
4.
Vos T, Lim SS, Abbafati C et al (2020) Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the global burden of disease study 2019. Lancet 396:1204–1222CrossRef
5.
Wang H, Abbas KM, Abbasifard M et al (2020) Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950–2019: a comprehensive demographic analysis for the global burden of disease study 2019. Lancet 396:1160–1203CrossRef
6.
Murray CJ, Aravkin AY, Zheng P et al (2020) Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the global burden of disease study 2019. Lancet 396:1223–1249CrossRef
7.
Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2019 (GBD 2019) Results. Seattle, United States: Institute for Health Metrics and Evaluation (IHME). Source: Institute for Health Metrics Evaluation. Used with permission. All rights reserved. Available from http://​ghdx.​healthdata.​org/​gbd-results-tool. Accessed: Jan-Feb 2021
8.
9.
Jabbour E, Fava C, Kantarjian H (2009) Advances in the biology and therapy of patients with chronic myeloid leukaemia. Best Pract Res Clin Haematol 22(3):395–407PubMedCrossRef
10.
Yamamoto JF, Goodman MT (2007) Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997–2002. Cancer Causes Control 19(4):379–390PubMedCrossRef
11.
Thygesen LC, Nielsen OJ, Johansen C (2009) Trends in adult leukemia incidence and survival in Denmark, 1943–2003. Cancer Causes Control 20(9):1671–1680PubMedCrossRef
12.
Berger U, Maywald O, Pfirrmann M et al (2005) Gender aspects in chronic myeloid leukemia: long-term results from randomized studies. Leukemia 19:984–989PubMedCrossRef
13.
Höglund M, Sandin F, Simonsson B (2015) Epidemiology of chronic myeloid leukaemia: an update. Ann Hematol 94(Suppl 2):S241-247PubMedCrossRef
14.
Bonner MR, Williams BA, Rusiecki JA et al (2010) Occupational exposure to terbufos and the incidence of cancer in the Agricultural Health Study. Cancer Causes Control 21(6):871–877PubMedPubMedCentralCrossRef
15.
16.
Poynter JN, Richardson M, Blair CK et al (2016) Obesity over the life course and risk of acute myeloid leukemia and myelodysplastic syndromes. Cancer Epidemiol 40:134–140PubMedCrossRef
17.
Weihe P, Spielmann J, Kielstein H et al (2020) Childhood Obesity and Cancer Risk in Adulthood. Curr Obes Rep 9:204–212PubMedCrossRef
18.
Shamriz O, Leiba M, Levine H et al (2017) Higher body mass index in 16–19 year-old Jewish Adolescents of North African, Middle Eastern and European Origins is a Predictor of Acute Myeloid Leukemia: a cohort of 2.3 million Israelis. Cancer Causes Control 28:331–339PubMedCrossRef
19.
20.
21.
Druker BJ, Guilhot F, O’Brien SG et al (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355(23):2408–2417PubMedCrossRef
22.
Bower H, Björkholm M, Dickman PW, Höglund M, Lambert PC, Andersson TM (2016) Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population. J Clin Oncol 34(24):2851–2857PubMedCrossRef
23.
Malhotra H, Radich J, Garcia-Gonzalez P (2019) Meeting the needs of CML patients in resource-poor countries. Hematology Am Soc Hematol Educ Program 2019(1):433–442PubMedPubMedCentralCrossRef
24.
Umeh CA, Garcia-Gonzalez P, Tremblay D, Laing R (2020) The survival of patients enrolled in a global direct-to-patient cancer medicine donation program: The Glivec International Patient Assistance Program (GIPAP). EClinicalMedicine 1(19):100257CrossRef
25.
Allemani C, Matsuda T, Di Carlo V et al (2018) Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 391(10125):1023–1075PubMedPubMedCentralCrossRef
26.
Navarrete M, Rossi E, Brivio E et al (2014) Treatment of childhood acute lymphoblastic leukemia in central America: A lower-middle income countries experience. Pediatr Blood Cancer 61(5):803–809PubMedCrossRef
27.
Gupta S, Yeh S, Martiniuk A et al (2013) The magnitude and predictors of abandonment of therapy in paediatric acute leukaemia in middle-income countries: a systematic review and meta-analysis. Eur J Cancer 49(11):2555–2564PubMedCrossRef
28.
Sharma R (2021) A Systematic Examination of Burden of Childhood Cancers in 183 Countries: Estimates from GLOBOCAN 2018. Eur J Cancer Care 30(5):e13438CrossRef
29.
Caniza MA, Odio C, Mukkada S et al (2015) Infectious complications in children with acute lymphoblastic leukemia treated in low-middle-income countries. Expert Rev Hematol 8(5):627–645PubMedCrossRef
30.
Hunger SP, Lu X, Devidas M et al (2012) Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children’s oncology group. J Clin Oncol 30(14):1663–1669PubMedPubMedCentralCrossRef
31.
Pulte D, Jansen L, Gondos A et al (2014) Survival of adults with acute lymphoblastic leukemia in Germany and the United States. PLoS ONE 9(1):e85554PubMedPubMedCentralCrossRef
32.
33.
Liu-Dumlao T, Kantarjian H, Thomas DA, O’Brien S, Ravandi F (2012) Philadelphia-positive acute lymphoblastic leukemia: current treatment options. Curr Oncol Rep 14(5):387–394PubMedPubMedCentralCrossRef
34.
Maino E, Sancetta R, Viero P et al (2014) Current and future management of Ph/BCR-ABL positive ALL. Expert Rev Anticancer Ther 14(6):723–740PubMedCrossRef
35.
Soverini S, Bassan R, Lion T (2019) Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: recent advances and remaining challenges. J Hematol Oncol 12:39PubMedPubMedCentralCrossRef
36.
Shah A, Andersson TM, Rachet B, Björkholm M, Lambert PC (2013) Survival and cure of acute myeloid leukaemia in E ngland, 1971–2006: a population–based study. Br J Haematol 162(4):509–516PubMedCrossRef
37.
Meyers J, Yu Y, Kaye JA, Davis KL (2013) Medicare fee-for-service enrollees with primary acute myeloid leukemia: an analysis of treatment patterns, survival, and healthcare resource utilization and costs. Appl Health Econ Health Policy 11(3):275–286PubMedCrossRef
38.
Smith M, Barnett M, Bassan R, Gatta G, Tondini C, Kern W (2004) Adult acute myeloid leukaemia. Crit Rev Oncol Hematol 50(3):197–222PubMedCrossRef
39.
Tallman MS, Wang ES, Altman JK et al (2019) Acute myeloid leukemia, version 3.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 17(6):721–49PubMedCrossRef
40.
Haferlach C, Dicker F, Schnittger S, Kern W, Haferlach T (2007) Comprehensive genetic characterization of CLL: a study on 506 cases analyzed with chromosome banding analysis, interphase FISH, IgV H status and immunophenotyping. Leukemia 21(12):2442–2451PubMedCrossRef
41.
Mrózek K, Eisfeld AK, Kohlschmidt J et al (2019) Complex karyotype in de novo acute myeloid leukemia: typical and atypical subtypes differ molecularly and clinically. Leukemia 33(7):1620–1634PubMedPubMedCentralCrossRef
42.
de Lira Benicio MT, Ribeiro AF, Américo AD et al (2017) Evaluation of the European Leukemia Net recommendations for predicting outcomes of patients with acute myeloid leukemia treated in low-and middle-income countries (LMIC): A Brazilian experience. Leuk Res 60:109–114CrossRef
43.
44.
Gupta S, Howard SC, Hunger SP et al (2015) Treating childhood cancer in low- and middle-income countries. In: Cancer: Disease Control Priorities, Vol. 3. The International Bank for Reconstruction and Development / The World Bank, Washington, DC
45.
Magrath I, Steliarova-Foucher E, Epelman S et al (2013) Improving cancer care for children and young people 2. Lancet Oncol 13:104–106CrossRef
46.
Lam CG, Howard SC, Bouffet E, Pritchard-Jones K (2019) Science and health for all children with cancer. Science 363(6432):1182–1186PubMedCrossRef
47.
Philip CC, Geoge B, Ganapule A et al (2014) Acute myeloid leukemia: Challenges and real world data from India. Blood 124(21):3685CrossRef
48.
49.
Knaul FM, Gonzalez-Pier E, Gomez-Dantes O et al (2012) The quest for universal health coverage: acheiving social protection for all in Mexico. Lancet 380:1259–1279PubMedCrossRef
50.
Antillon F, Baez F, Barrantes Zamorra JC (2005) AMOR: a proposed cooperative effort to improve outcomes of childhood cancer in Central America. Pediatr Blood Cancer 45:107–110PubMedCrossRef
51.
Mostert S, Sitaresmi MN, Gundy CM et al (2010) Comparing childhood leukaemia treatment before and after the introduction of a parental education programme in Indonesia. Arch Dis Child 95:20–25PubMedCrossRef
52.
Israels T, Borgstein E, Pidini D et al (2012) Managment of children with a Wilms tumor in Malawi, sub-saharan Africa. J Pediatr Hematol Oncol 34:606–610PubMedCrossRef
53.
Howard SC, Metzger ML, Wilimas JA et al (2008) Childhood cancer epidemiology in low-income countries. Cancer 112:461–472PubMedCrossRef
54.
Metadaten
Titel
Mapping incidence and mortality of leukemia and its subtypes in 21 world regions in last three decades and projections to 2030
verfasst von
Rajesh Sharma
Chinmay Jani
Publikationsdatum
10.05.2022
Verlag
Springer Berlin Heidelberg
Erschienen in
Annals of Hematology / Ausgabe 7/2022
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-022-04843-6

Weitere Artikel der Ausgabe 7/2022

Polatuzumab vedotin combined with rituximab-bendamustine immediately before stem cell mobilization in relapsed diffuse large B-cell lymphoma

  • Letter to the Editor

Comparison of daily oral iron replacement therapy with every other day treatment in female reproductive age patients with iron-deficiency anemia

  • Original Article

COVID-19: impact of vaccination in myeloma patients

  • Zur Zeit gratis
  • COVID-19
  • Letter to the Editor

Red eye and visual loss in a bone marrow transplant recipient

  • Letter to the Editor

Left atrial deformation indices in β-thalassemia major patients

  • Original Article

Prognostic impact of Auer rods for cytoreductive chemotherapy and myeloablative allogeneic stem cell transplantation in adult patients with myelodysplastic syndrome with excess blasts-2

  • Letter to the Editor

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Viele erhielten in der Pandemie zu früh Sauerstoff

Die Entscheidung zur Sauerstofftherapie in Notaufnahmen variierte in Italien während der Corona-Pandemie stark zwischen den einzelnen Kliniken. Oft entschieden sich Ärzte und Ärztinnen jedoch früher als nötig für eine Behandlung mit Sauerstoff.

Zufällig entdeckter Barrett-Ösophagus nicht weniger risikobehaftet

Fälle von Barrett-Ösophagus, die bei einer ÖGD als Zufallsbefund zutage treten, sind keine Seltenheit und auch keineswegs harmloser als Barrett-Metaplasien, die bei gezieltem Screening oder Surveillance-Untersuchungen entdeckt werden. 

Eosinophile Ösophagitis: Doppelte Dosis PPI wirkt besser

Protonenpumpenhemmer führen bei eosinophiler Ösophagitis nur in etwa jedem zweiten Fall zu einer klinischen bzw. histologischen Remission, so das Ergebnis einer Metaanalyse. Verbessern lässt sich die Quote möglicherweise mit einer Dosisverdopplung und der Aufteilung der Tagesdosis.

Testosterontherapie bei Klinefelter-Syndrom senkt Sterblichkeit

Das Klinefelter-Syndrom bleibt bei vielen Männern unerkannt – und selbst nach einer Diagnose erhalten Betroffene oft keine Testosteronersatztherapie. Eine dänische Studie zeigt jedoch, dass eine solche Behandlung die Mortalität um nahezu 50% senken kann.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Jetzt 10 CME-Punkte sammeln

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise